Kowa has our backs and this is why…

[anonymous]

Kowa has our backs simply because they could have actually laid all the sales reps off when you think about it. They are trying to keep job security for us. Unlike Amarin if you recall they laid off all their reps completely. With Vascepa generics flooded the market but with Livalo sale reps have always sold against a huge market of generics and Livalo annually produced revenue of $500-$600 million a year.

Do we question some of the leaders recent decisions like launching SEG yes. In the end we are optimistic! Bring on 2024!

 

[anonymous]

Kowa has our backs simply because they could have actually laid all the sales reps off when you think about it. They are trying to keep job security for us. Unlike Amarin if you recall they laid off all their reps completely. With Vascepa generics flooded the market but with Livalo sale reps have always sold against a huge market of generics and Livalo annually produced revenue of $500-$600 million a year.

Do we question some of the leaders recent decisions like launching SEG yes. In the end we are optimistic! Bring on 2024!

Thanks for that Pollyanna. I would have guessed Jeff, but he would have never questioned his own judgement, even in jest. So, what are you going to be doing until the savior product comes next year? Selling Blink for Livalo? The best in the company barely got a bonus. Kowa will keep everyone. They lost money on Livalo for 7 years. They have a product coming eventually in that Ophthalmology space but that sales force like all sales forces in that space will be 120. If you aren't in a major metro market with population density keep looking the grass is truly greener elsewhere. I just hope Kowa sees what leadership did to a once great culture and cleans house. The OTC division is going to be the spies that may do just that.

 

[anonymous]

Kowa has our backs simply because they could have actually laid all the sales reps off when you think about it. They are trying to keep job security for us. Unlike Amarin if you recall they laid off all their reps completely. With Vascepa generics flooded the market but with Livalo sale reps have always sold against a huge market of generics and Livalo annually produced revenue of $500-$600 million a year.

Do we question some of the leaders recent decisions like launching SEG yes. In the end we are optimistic! Bring on 2024!

Are you mental?

 

[anonymous]

Are you mental?

 

[anonymous]

Kowa has our backs simply because they could have actually laid all the sales reps off when you think about it. They are trying to keep job security for us. Unlike Amarin if you recall they laid off all their reps completely. With Vascepa generics flooded the market but with Livalo sale reps have always sold against a huge market of generics and Livalo annually produced revenue of $500-$600 million a year.

Do we question some of the leaders recent decisions like launching SEG yes. In the end we are optimistic! Bring on 2024!

Love the optimism but let's be realistic. Kowa can't lay off all of the reps. The next drug will more than likely be a co-promote. What company in their right mind would agree to a co-promote with kowa if kowa had no sales force. I guarantee if the terms fall through and the agreement ends up being dead in the water, the reps will get laid off. It has nothing to do with them being nice and trying to keep their reps around and everything to do with making Kowa appealing to a co-promote. At least we will all most likely have jobs through the holidays so I won't complain, but I won't be delusional about why we're still here either.

 

[anonymous]

Love the optimism but let's be realistic. Kowa can't lay off all of the reps. The next drug will more than likely be a co-promote. What company in their right mind would agree to a co-promote with kowa if kowa had no sales force. I guarantee if the terms fall through and the agreement ends up being dead in the water, the reps will get laid off. It has nothing to do with them being nice and trying to keep their reps around and everything to do with making Kowa appealing to a co-promote. At least we will all most likely have jobs through the holidays so I won't complain, but I won't be delusional about why we're still here either.

good point

 

[anonymous]

Love the optimism but let's be realistic. Kowa can't lay off all of the reps. The next drug will more than likely be a co-promote. What company in their right mind would agree to a co-promote with kowa if kowa had no sales force. I guarantee if the terms fall through and the agreement ends up being dead in the water, the reps will get laid off. It has nothing to do with them being nice and trying to keep their reps around and everything to do with making Kowa appealing to a co-promote. At least we will all most likely have jobs through the holidays so I won't complain, but I won't be delusional about why we're still here either.

I agree!